Merck & Co., Inc: Sleep Initiation and Maintenance Disorders trials
The registry lists 20 Sleep Initiation and Maintenance Disorders studies with Merck & Co., Inc as lead sponsor. 1 are open to participants now and 16 have results posted.
Phase 1 7Phase 2 2Phase 3 11(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study of Suvorexant (MK-4305) for the Treatment of Insomnia Disorder in Participants With Opioid Use Disorder (MK-4305-098)RecruitingNCT06655883Phase 3
- Safety and Efficacy of Suvorexant (MK-4305) for the Treatment of Insomnia in Participants With Alzheimer's Disease (MK-4305-061)CompletedNCT02750306Phase 3Results posted
- Effects of Suvorexant in Participants With Obstructive Sleep Apnea (MK-4305-036)CompletedNCT01300455Phase 1Results posted
- Effects of Suvorexant in Patients With Chronic Obstructive Pulmonary Disease (MK-4305-032)CompletedNCT01293006Phase 1Results posted
- Safety and Efficacy Study of Suvorexant in Participants With Primary Insomnia - Study B (MK-4305-029)CompletedNCT01097629Phase 3Results posted
- Safety and Efficacy Study of Suvorexant in Participants With Primary Insomnia - Study A (MK-4305-028)CompletedNCT01097616Phase 3Results posted
- Pharmacokinetics of Suvorexant in Participants With Impaired Renal Function (MK-4305-023)(COMPLETED)CompletedNCT01059851Phase 1Results posted
- Pharmacokinetics of Suvorexant in Participants With Hepatic Insufficiency (MK-4305-017)CompletedNCT01043926Phase 1Results posted
- Polysomnography Study of MK-6096 in Participants With Primary Insomnia (MK-6096-011)CompletedNCT01021852Phase 2Results posted
- A Long Term Safety Study of Suvorexant in Participants With Primary Insomnia (MK-4305-009 AM3)CompletedNCT01021813Phase 3Results posted
- Phase IIB 2-Period Crossover Polysomnography Study in Participants With Primary Insomnia (MK-4305-006)CompletedNCT00792298Phase 2Results posted
- Twenty-six Week Extension Trial of Org 50081 (Esmirtazapine) in Outpatients With Chronic Primary Insomnia (176003/P05721/MK-8265-007)TerminatedNCT00750919Phase 3Results posted
- A 6-Month Efficacy and Safety Study of Org 50081 in Adult Patients With Chronic Primary Insomnia (21106/P05701/MK-8265-002)CompletedNCT00631657Phase 3Results posted
- Fifty Two Week Extension Trial of Org 50081 (Esmirtazapine) in the Treatment of Insomnia (P05708)CompletedNCT00610675Phase 3Results posted
- Efficacy and Safety Study of Org 50081 (Esmirtazapine) in Elderly Participants (P05709)CompletedNCT00561821Phase 3Results posted
- A Six Week, Double-Blind Randomized, Efficacy and Safety, Sleep Lab Trial With Esmirtazapine (Org 50081) (P05707)CompletedNCT00506389Phase 3Results posted
- Study of the Safety and Effectiveness of Esmirtazapine in Participants With Chronic Primary Insomnia (P05706)CompletedNCT00482612Phase 3Results posted
- A Study to Evaluate Next Day Effects of MK-4305 on Driving Performance (MK-4305-035 AM1)CompletedNCT01311882Phase 1
- Effects of Insomnia on Simulated Driving (MK-0000-183-00)CompletedNCT01209728Phase 1
- A Study to Assess the Effect of Single and Multiple Doses Org 50081 and a Single Dose of Zopiclone on Next-day Driving Ability and Psychomotor Performance in Healthy Volunteers. (P05794) (COMPLETED)CompletedNCT00798395Phase 1